ORGO Organogenesis Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORGO

Price (delayed)

$2.43

Market cap

$312.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.15

Enterprise value

$291.44M

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 13
Relative Valuation: Rel. Valuation: 59
Relative Profitability: Rel. Profitability: 51

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's ...

Highlights
The EPS has dropped by 194% since the previous quarter but it is up by 12% year-on-year
The net income has soared by 117% YoY but it has plunged by 93% from the previous quarter
ORGO's equity is down by 19% QoQ
The quick ratio has declined by 16% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.organogenesis.com
Peers: OPK

Key stats

What are the main financial stats of ORGO

ORGO stock price

How has the Organogenesis Holdings stock price performed over time
Intraday
0.41%
1 week
0%
1 month
-5.45%
1 year
-33.61%
YTD
-53.09%
QTD
2.53%

Financial performance

How have Organogenesis Holdings's revenue and profit performed over time
Revenue
$514.7M
Gross profit
$375.13M
Operating income
$2.55M
Net income
$2.72M
Gross margin
72.9%
Net margin
0.5%
The net income has soared by 117% YoY but it has plunged by 93% from the previous quarter
ORGO's net margin has soared by 114% year-on-year but it has dropped by 92% since the previous quarter
Organogenesis Holdings's operating income has soared by 111% YoY but it has plunged by 94% from the previous quarter
Organogenesis Holdings's operating margin has surged by 109% YoY but it has shrunk by 94% QoQ

Price vs fundamentals

How does ORGO's price correlate with its fundamentals

Growth

What is Organogenesis Holdings's growth rate over time

Valuation

What is Organogenesis Holdings stock price valuation
ORGO P/E details
P/E
N/A
P/B
1.28
P/S
0.6
EV/EBIT
98.46
EV/EBITDA
8.1
EV/Sales
0.57
The EPS has dropped by 194% since the previous quarter but it is up by 12% year-on-year
The P/B is 47% below the 5-year quarterly average of 2.4 and 33% below the last 4 quarters average of 1.9
ORGO's equity is down by 19% QoQ
ORGO's P/S is 54% below its 5-year quarterly average of 1.3 and 40% below its last 4 quarters average of 1.0
The company's revenue rose by 12% YoY but it fell by 9% QoQ

Efficiency

How efficient is Organogenesis Holdings business performance
Organogenesis Holdings's return on equity has shrunk by 192% QoQ but it has increased by 8% YoY
The ROA has plunged by 192% from the previous quarter but it has grown by 18% YoY
The return on sales has surged by 112% year-on-year but it has dropped by 92% since the previous quarter
The return on invested capital has surged by 111% year-on-year but it has dropped by 94% since the previous quarter

Dividends

What is ORGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORGO.

Financial health

How did Organogenesis Holdings financials performed over time
Organogenesis Holdings's total liabilities has increased by 40% YoY but it has decreased by 16% QoQ
The quick ratio has declined by 16% year-on-year and by 12% since the previous quarter
ORGO's debt is 71% smaller than its equity
ORGO's debt has soared by 66% year-on-year but it is down by 14% since the previous quarter
The debt to equity has soared by 61% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.